South San Francisco-based Denali Therapeutics Inc, which is focused on developing treatments for patients with neurodegenerative diseases, has raised $130 million in Series B financing. Baillie Gifford led the round with participation from other investors that included ARCH Venture Partners, F-Prime Biosciences, Flagship Ventures and the Alaska Permanent Fund.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: